OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: James Reynolds who started this subject	7/27/2004 4:35:44 PM
From: A.J. Mullen	of 447

These tyrosine-kinase inhibitors only seem to work on 10% of the population. A better play might be any company that tests the tumours to see if it has the EGFR mutations that suggest it will be susceptible to the inhibitors. BAck in May when the Science and NEJM articles came out there were no commercial tests but they were being developed. I was told "maybe by late summer." Has anyone heard anything? In the meantime, it seems that anyone who has lung despite never having smoked should take Iressa, TArceva, or perhaps some other tyrosine-kinase inhibitor. Ashley

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next